India Plan To Fund Pharma R&D Meets Consumer Objections
This article was originally published in PharmAsia News
An effort by the Indian government to contribute funds to help encourage more pharmaceutical research and development in the country has encountered objections from public interest groups. The government plan would allow drugs developed as a result of the funds to be patented. The groups say it is not fair to allow drugs developed with public money to be granted patents, saying the grant of a monopoly on marketing the drugs would cause them to be more expensive to the general public. (Click here for more
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.